RECURSION PHARMACEUTICALS, INC.

(RXRX)
  Report
Delayed Nasdaq  -  04:00 2022-08-16 pm EDT
12.32 USD   -4.94%
08/11Goldman Sachs Adjusts Recursion Pharmaceuticals' Price Target to $8 From $7, Keeps Neutral Rating
MT
08/09RECURSION PHARMACEUTICALS : Q2 Earnings Snapshot
AQ
08/09RECURSION PHARMACEUTICALS : Provides Business Updates and Reports Second Quarter 2022 Financial Results - Form 8-K
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Evolution of the average Target Price on RECURSION PHARMACEUTICALS, INC.
Target Price consensus revisions : last 18 months
Recommendations (Chart) RECURSION PHARMACEUTICALS, INC.
Analyst Recommendations on RECURSION PHARMACEUTICALS, INC.
08/11Goldman Sachs Adjusts Recursion Pharmaceuticals' Price Target to $8 From $7, Keeps Neutral..
MT
06/22Berenberg Bank Adjusts Recursion Pharmaceuticals' Price Target to $38 From $36, Maintains ..
MT
05/24Goldman Sachs Lowers Recursion Pharmaceuticals' Price Target to $7 From $9, Neutral Rating..
MT
04/18BofA Securities Downgrades Recursion Pharmaceuticals to Neutral from Buy
MT
03/24Goldman Sachs Adjusts Recursion Pharmaceuticals' Price Target to $10 from $32, Keeps Neutr..
MT
03/04SVB Leerink Downgrades Recursion Pharmaceuticals to Market Perform from Outperform, Adjust..
MT
03/04Berenberg Bank Trims Recursion Pharmaceuticals' Price Target to $36 From $37 on Delayed RE..
MT
More recommendations
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Last Close Price 12,32 $
Average target price 16,20 $
Spread / Average Target 31,5%
High Price Target 38,00 $
Spread / Highest target 208%
Low Price Target 8,00 $
Spread / Lowest Target -35,1%
Consensus detail
Consensus revision (last 18 months)